Litcius/Paper detail

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders

Luisa Agnello, Bruna Lo Sasso, Matteo Vidali, Concetta Scazzone, Caterina Maria Gambino, Tommaso Piccoli, Giulia Bivona, Anna Maria Ciaccio, Rosaria Vincenza Giglio, Vincenzo La Bella, Marcello Ciaccio

2022Journal of Clinical Medicine13 citationsDOIOpen Access PDF

Abstract

(1) Background: Alpha-synuclein (α-syn) is a presynaptic neuronal protein that regulates several neuronal functions. In recent decades, the role of α-syn as a biomarker of neurodegenerative diseases has been explored, especially in synucleinopathies. However, only a few studies have assessed its role as biomarker in other neurological disorders. The aim of the study was to evaluate cerebrospinal fluid (CSF) α-syn levels in several neurological disorders; (2) Methods: We measured CSF α-syn levels by a commercial ELISA kit in 158 patients classified in the following group: controls, Alzheimer’s Disease (AD), cerebrovascular diseases, inflammatory central nervous system diseases, other neurological diseases, Parkinson’s Disease (PD), and peripheral neuropathy; (3) Results: Patients with PD showed the lowest and patients with AD the highest levels of CSF α-syn (1372 vs. 2912 pg/mL, respectively, p < 0.001). In AD patients, α-syn levels were significantly associated with tau proteins; (4) Conclusions: α-syn could represent a biomarker of neurodegenerative diseases.

Topics & Concepts

MedicineCerebrospinal fluidBiomarkerSynucleinopathiesAlpha-synucleinDiseaseAlpha (finance)NeurologyParkinson's diseaseInternal medicinePathologyPsychiatrySurgeryChemistryBiochemistryPatient satisfactionConstruct validityParkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatmentsBotulinum Toxin and Related Neurological Disorders